Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.64 |
| ▸ | FLT3 | P36888 | 2/20 | 0.63 |
| ▸ | F7 | P08709 | 1/20 | 0.59 |
| ▸ | F3 | P13726 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PYGL | P06737 | 5/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6173150 | 0.89 | FLT3 (0.59) | HRH4FLT3F7F3PDGFRB | |
| SCHEMBL3253061 | 0.85 | HRH4 (0.70) | HRH4FLT3F7F3HRH3 | |
| SCHEMBL2717168 | 0.84 | PDGFRB (0.70) | FLT3PDGFRBMEN1NPC1RAB9A | |
| SCHEMBL22529383 | 0.83 | FLT3 (0.63) | HRH4FLT3PDGFRBHRH3MEN1 | |
| SCHEMBL2138562 | 0.83 | FLT3 (0.63) | HRH4FLT3PDGFRBPDGFRA | |
| SCHEMBL6170623 | 0.82 | ATP6AP1 (0.44) | HRH4FLT3PDGFRBMEN1KMT2A | |
| SCHEMBL3246966 | 0.81 | PDGFRB (0.57) | FLT3PDGFRBNPC1RAB9APDGFRA | |
| SCHEMBL2642882 | 0.80 | HRH4 (0.53) | HRH4FLT3PDGFRBKMT2APYGL | |
| SCHEMBL3963537 | 0.79 | F7 (0.66) | HRH4FLT3F7F3PDGFRB | |
| SCHEMBL31219213 | 0.79 | F7 (0.66) | HRH4FLT3F7F3PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| EP-1651639-B1 | BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS | ARPIDA AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-7598398-B2 | Acyl indoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7524854-B2 | Benzofuran derivatives and their use in the treatment of microbial infections | ARPIDA AG (CH) | 2009-04-28 | — | — | US | disclosed |
| US-20070088071-A1 | Acyl indoles, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2007-04-19 | — | — | US | disclosed |
| US-20060154943-A1 | Benzofuran derivatives and their use in the treatment of microbial infections | ARPIDA AG (CH) | 2006-07-13 | — | — | US | disclosed |
| EP-1651639-A1 | BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS | Arpida AG, (CH) | 2006-05-03 | — | — | EP | disclosed |
| EP-1045833-B1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005005418-A1 | BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS | ARPIDA AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1045833-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035130-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | HRH4 2307/4885FLT3 2154/4885F7 2480/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | HRH4 2307/4885FLT3 2154/4885F7 2480/4885 |
| US-20060154943-A1 | Benzofuran derivatives and their use in the treatment of microbial infections | DCXR, NLRP3, NISCH | HRH4 1582/4885FLT3 880/4885F7 2244/4885 |
| US-20070088071-A1 | Acyl indoles, compositions containing such compounds and methods of use | GPR119, IAPP, GLP1R | HRH4 666/4885FLT3 2694/4885F7 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.